Your browser does not support JavaScript!

Matières premières

351 entreprises et organismes intervenants dans le domaine 'Matières premières', classés par activité.

Rejoignez la communauté
ABBOTT
est cité dans une actualité de FierceBiotech
Il y a 2 jours

Abbott partners with Omada, Tandem to extend the reach of its FreeStyle Libre CGM

Il y a 3 jours
Abbott has teamed up with Omada Health to offer its FreeStyle Libre continuous glucose monitoring system through the latter’s digital care program for people with type 2 diabetes. Abbott also...
www.fiercebiotech.com
MERCK MILLIPORE
est cité dans une actualité de FierceBiotech
Il y a 1 semaine

EuroBiotech Report—UCB inks $2.5B deal; Oxford spinout; Bayer, Merck and Gilead

Il y a 1 semaine
In this week's EuroBiotech Report, UCB inks $2.5 billion Ra takeout, MiroBio raises £27 million and Bayer forms Riken drug discovery pact. ...
www.fiercebiotech.com
MERCK MILLIPORE
est cité dans une actualité de Labiotech.eu
Il y a 1 semaine

UK Company and Merck Team Up to Develop Vaccines Based on the Microbiome

Il y a 1 semaine
Merck will pay the microbiome company 4D Pharma up to €316.5M to develop vaccines based on delivering live bacteria to the gut. The partners will develop vaccines against three undisclosed conditions....
www.labiotech.eu
MERCK MILLIPORE
est cité dans une actualité de FierceBiotech
Il y a 2 semaines

ESMO: AbbVie's PARP inhibitor veliparib finally gets a win, but can it compete?

Il y a 2 semaines
BARCELONA—Quietly, and without the fanfare of gene and cell therapies, PARP inhibitors from the likes of AstraZeneca, Merck and GlaxoSmithKline/Tesaro have been racking up big trial wins in breast and...
www.fiercebiotech.com
ABBOTT
est cité dans une actualité de FierceBiotech
Il y a 2 semaines

Abbott shows off 6-month TriClip data for tricuspid valve repair at TCT

Il y a 2 semaines
Just weeks after Abbott launched a large, randomized trial of its TriClip device, the devicemaker presented new data from a smaller, single-arm analysis showing clinical improvements after six months....
www.fiercebiotech.com
ABBOTT
est cité dans une actualité de FierceBiotech
Il y a 3 semaines

Abbott's highly sensitive troponin blood test for heart attacks cleared by FDA

Il y a 3 semaines
Abbott has secured FDA clearance for its highly sensitive troponin blood test, which aims to identify heart attacks hours earlier than previous methods. Its Architect Stat test searches for small...
www.fiercebiotech.com
MERCK MILLIPORE
est cité dans une actualité de FierceBiotech
Le 20/09/2019

Black Diamond grabs trio of new R&D execs as it barrels toward the clinic

Le 19/09/2019
After a whirlwind year and two quick-fire raises, cancer startup Black Diamond Therapeutics has nabbed Yumanity, Merck KGaA and SR One veterans to help head up its research work....
www.fiercebiotech.com
ABBOTT
est cité dans une actualité de FierceBiotech
Le 19/09/2019

Abbott nets European approvals for 2 implants to fix heart defects in newborns

Le 17/09/2019
Abbott has received European approvals for two devices designed for children and infants with life-threatening heart defects—including the world’s smallest mechanical heart valve and a separate...
www.fiercebiotech.com
MERCK MILLIPORE
est cité dans une actualité de FierceBiotech
Le 18/09/2019

Merck's Ebola vaccine tees up FDA date, aiming for first status

Le 17/09/2019
Merck will learn whether the FDA will approve its Ebola vaccine V920 by mid-March, giving it a shot at becoming the first company to receive clearance to sell a vaccine against the virus in the U.S....
www.fiercebiotech.com
ABBOTT
est cité dans une actualité de FierceBiotech
Le 09/09/2019

Abbott launches large trial of its tricuspid valve repair device

Le 06/09/2019
Abbott has begun its first randomized, pivotal trial to test a new method of fixing leaky tricuspid heart valves, where there are currently no approved minimally invasive repair therapies available....
www.fiercebiotech.com
Charger plus d'actualités